The year in atherothrombosis

Journal of the American College of Cardiology

Volumn 58, Issue 8, 2011, Pages 779-791

  Sanz, Javier ^a   Fuster, Valentin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; imaging; risk factors; thrombosis; vasculature

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANACETRAPIB; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; NICOTINIC ACID; OMEPRAZOLE; PIOGLITAZONE; PLACEBO; PRASUGREL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SIMVASTATIN; TICAGRELOR; TORCETRAPIB; TRIACYLGLYCEROL; VALSARTAN;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DYSLIPIDEMIA; GASTROINTESTINAL HEMORRHAGE; GENETIC MARKER; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MOLECULAR IMAGING; MORTALITY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SYSTOLIC HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL;

ANKLE BRACHIAL INDEX; ANTI-OBESITY AGENTS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCINOSIS; CORONARY DISEASE; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DYSLIPIDEMIAS; ENDARTERECTOMY; FIBRINOLYTIC AGENTS; GENETIC MARKERS; HEALTH BEHAVIOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIFE STYLE; LIPIDS; METABOLIC SYNDROME X; NATRIURETIC PEPTIDE, BRAIN; OBESITY; RISK ASSESSMENT; RISK FACTORS; SMOKING CESSATION; STENTS; STROKE; THROMBOSIS; TROPONIN I;

EID: 80051613139     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.03.052     Document Type: Review

References (118)

1. H.C. Wijeysundera, M. Machado, and F. Farahati Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 19942005 JAMA 303 2010 1841 1847
2. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment, and control of hypertension, 19882008 JAMA 303 2010 2043 2050
3. J.D. Cohen, M.J. Cziraky, and Q. Cai 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 19992006 Am J Cardiol 106 2010 969 975
4. G.A. Nichols, B.M. Ambegaonkar, V. Sazonov, and J.B. Brown Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy Am J Cardiol 104 2009 1689 1694
5. S.T. Stewart, D.M. Cutler, and A.B. Rosen Forecasting the effects of obesity and smoking on U.S. life expectancy N Engl J Med 361 2009 2252 2260
6. C.G. Magnussen, J. Koskinen, and W. Chen Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study Circulation 122 2010 1604 1611
7. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 19992008 JAMA 303 2010 235 241
8. C.L. Ogden, M.D. Carroll, L.R. Curtin, M.M. Lamb, and K.M. Flegal Prevalence of high body mass index in US children and adolescents, 20072008 JAMA 303 2010 242 249
9. D.L. Bhatt, K.A. Eagle, and E.M. Ohman Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis JAMA 304 2010 1350 1357
10. A. Goyal, D.L. Bhatt, and P.G. Steg Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countries Circulation 122 2010 1167 1175
11. V. Fuster, and B.B. Kelly Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health 2010 National Academies Press Washington, DC
12. K.C. Koskinas, C.L. Feldman, and Y.S. Chatzizisis Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study Circulation 121 2010 2092 2101
13. M. Markl, F. Wegent, and T. Zech In vivo wall shear stress distribution in the carotid artery: effect of bifurcation geometry, internal carotid artery stenosis, and recanalization therapy Circ Cardiovasc Imaging 3 2010 647 655
14. Z.Y. Li, U. Sadat, and J. U-King-Im Association between aneurysm shoulder stress and abdominal aortic aneurysm expansion: a longitudinal follow-up study Circulation 122 2010 1815 1822
15. M. Drechsler, R.T. Megens, M. van Zandvoort, C. Weber, and O. Soehnlein Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis Circulation 122 2010 1837 1845
16. M.G. Ionita, P. van den Borne, and L.M. Catanzariti High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions Arterioscler Thromb Vasc Biol 30 2010 1842 1848
17. F. Montecucco, S. Lenglet, and A. Gayet-Ageron Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke Stroke 41 2010 1394 1404
18. C. de Oliveira, R. Watt, and M. Hamer Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey BMJ 340 2010 c2451
19. S. Jelic, D.J. Lederer, and T. Adams Vascular inflammation in obesity and sleep apnea Circulation 121 2010 1014 1021
20. M. Gossl, D. Versari, and H.A. Hildebrandt Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis J Am Coll Cardiol Img 3 2010 32 40
21. W.E. Hellings, W. Peeters, and F.L. Moll Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study Circulation 121 2010 1941 1950
22. M.C. Kramer, S.Z. Rittersma, and R.J. de Winter Relationship of thrombus healing to underlying plaque morphology in sudden coronary death J Am Coll Cardiol 55 2010 122 132
23. G. Ferrante, M. Nakano, and F. Prati High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study Circulation 122 2010 2505 2513
24. J.R. Enriquez, and J.A. de Lemos Should we focus on novel risk markers and screening tests to better predict and prevent cardiovascular disease? Point Prev Cardiol 13 2010 152 159
25. J.T. Wilkins, and D.M. Lloyd-Jones Biomarkers for coronary heart disease clinical risk prediction: a critical appraisal Counterpoint Prev Cardiol 13 2010 160 165
26. P. Greenland, J.S. Alpert, and G.A. Beller 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2010 e50 e103
27. M.J. O'Donnell, D. Xavier, and L. Liu Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study Lancet 376 2010 112 123
28. H.W. Querfurth, and F.M. LaFerla Alzheimer's disease N Engl J Med 362 2010 329 344
29. V. Novak, and I. Hajjar The relationship between blood pressure and cognitive function Nat Rev Cardiol 7 2010 686 698
30. V.J. Carey, L. Bishop, N. Laranjo, B.J. Harshfield, C. Kwiat, and F.M. Sacks Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control Am J Cardiol 106 2010 757 763
31. P.M. Ridker, J. Genest, and S.M. Boekholdt HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
32. P.M. Rothwell, S.C. Howard, and E. Dolan Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Lancet 375 2010 895 905
33. N. Sarwar, P. Gao, and S.R. Seshasai Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
34. M.S. Dhamoon, and M.S. Elkind Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease Circulation 121 2010 2071 2078
35. J. Arnlov, E. Ingelsson, J. Sundstrom, and L. Lind Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men Circulation 121 2010 230 236
36. S. Mottillo, K.B. Filion, and J. Genest The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis J Am Coll Cardiol 56 2010 1113 1132
37. A. Mente, S. Yusuf, and S. Islam Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries J Am Coll Cardiol 55 2010 2390 2398
38. O. Bayturan, E.M. Tuzcu, and A. Lavoie The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis Arch Intern Med 170 2010 478 484
39. M.H. Criqui, R.L. McClelland, and M.M. McDermott The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis) J Am Coll Cardiol 56 2010 1506 1512
40. G.F. Mitchell, S.J. Hwang, and R.S. Vasan Arterial stiffness and cardiovascular events: the Framingham Heart Study Circulation 121 2010 505 511
41. E. Selvin, M.W. Steffes, and H. Zhu Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults N Engl J Med 362 2010 800 811
42. J. Zacho, A. Tybjaerg-Hansen, and B.G. Nordestgaard C-reactive protein and all-cause mortalitythe Copenhagen City Heart Study Eur Heart J 31 2010 1624 1632
43. S. Kaptoge, E. Di Angelantonio, and G. Lowe C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
44. E.Y. Yang, V. Nambi, and Z. Tang Clinical implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk In Communities) study J Am Coll Cardiol 54 2009 2388 2395
45. J.P. Corsetti, D. Ryan, D.L. Rainwater, A.J. Moss, W. Zareba, and C.E. Sparks Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels Arterioscler Thromb Vasc Biol 30 2010 1657 1664
46. E. Di Angelantonio, R. Chowdhury, and N. Sarwar B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies Circulation 120 2009 2177 2187
47. T. Omland, J.A. de Lemos, and M.S. Sabatine A sensitive cardiac troponin T assay in stable coronary artery disease N Engl J Med 361 2009 2538 2547
48. C.R. deFilippi, J.A. de Lemos, and R.H. Christenson Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults JAMA 304 2010 2494 2502
49. S. Blankenberg, T. Zeller, and O. Saarela Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) biomarker project Circulation 121 2010 2388 2397
50. W. Hochholzer, D.A. Morrow, and R.P. Giugliano Novel biomarkers in cardiovascular disease: update 2010 Am Heart J 160 2010 583 594
51. A. Malarstig, and A. Hamsten Genetics of atherothrombosis and thrombophilia Curr Atheroscler Rep 12 2010 159 166
52. S. Ripatti, E. Tikkanen, and M. Orho-Melander A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses Lancet 376 2010 1393 1400
53. S. Rosenberg, M.R. Elashoff, and P. Beineke Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients Ann Intern Med 153 2010 425 434
54. N.P. Paynter, D.I. Chasman, and G. Pare Association between a literature-based genetic risk score and cardiovascular events in women JAMA 303 2010 631 637
55. S. Dandona, A.F. Stewart, and L. Chen Gene dosage of the common variant 9p21 predicts severity of coronary artery disease J Am Coll Cardiol 56 2010 479 486
56. P. Willeit, J. Willeit, and A. Brandstatter Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk Arterioscler Thromb Vasc Biol 30 2010 1649 1656
57. J.L. Mega, S.L. Close, and S.D. Wiviott Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
58. V. Fuster, and J.M. Sweeny Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle JAMA 304 2010 1839 1840
59. L. Wallentin, S. James, and R.F. Storey Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
60. S.J. Nicholls, A. Hsu, and K. Wolski Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome J Am Coll Cardiol 55 2010 2399 2407
61. O. Bayturan, S. Kapadia, and S.J. Nicholls Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol J Am Coll Cardiol 55 2010 2736 2742
62. T. Kubo, A. Maehara, and G.S. Mintz The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization J Am Coll Cardiol 55 2010 1590 1597
63. V. Nambi, L. Chambless, and A.R. Folsom Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study J Am Coll Cardiol 55 2010 1600 1607
64. C. Giannarelli, B. Ibanez, and G. Cimmino Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis J Am Coll Cardiol Img 3 2010 1256 1264
65. J.P. Parmar, W.J. Rogers, and J.P. Mugler Magnetic resonance imaging of carotid atherosclerotic plaque in clinically suspected acute transient ischemic attack and acute ischemic stroke Circulation 122 2010 2031 2038
66. T.S. Polonsky, R.L. McClelland, and N.W. Jorgensen Coronary artery calcium score and risk classification for coronary heart disease prediction JAMA 303 2010 1610 1616
67. B.J. Chow, G.A. Wells, and L. Chen Prognostic value of 64-slice cardiac computed tomography severity of coronary artery disease, coronary atherosclerosis, and left ventricular ejection fraction J Am Coll Cardiol 55 2010 1017 1028
68. T.N. Kim, S. Kim, and S.J. Yang Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography Circ Cardiovasc Imaging 3 2010 142 148
69. R.R. Moustafa, D. Izquierdo-Garcia, and T.D. Fryer Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study Circ Cardiovasc Imaging 3 2010 536 541
70. F. Pugliese, O. Gaemperli, and A.R. Kinderlerer Imaging of vascular inflammation with [11C]-PK11195 and positron emission tomography/computed tomography angiography J Am Coll Cardiol 56 2010 653 661
71. A. Klink, E. Lancelot, and S. Ballet Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe Arterioscler Thromb Vasc Biol 30 2010 403 410
72. D.P. Cormode, E. Roessl, and A. Thran Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles Radiology 256 2010 774 782
73. J. Suzuki, M. Ogawa, and K. Takayama Ultrasound-microbubble-mediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice J Am Coll Cardiol 55 2010 904 913
74. K. Bibbins-Domingo, G.M. Chertow, and P.G. Coxson Projected effect of dietary salt reductions on future cardiovascular disease N Engl J Med 362 2010 590 599
75. H.M. Johnson, L.K. Gossett, and M.E. Piper Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial J Am Coll Cardiol 55 2010 1988 1995
76. I. Shai, J.D. Spence, and D. Schwarzfuchs Dietary intervention to reverse carotid atherosclerosis Circulation 121 2010 1200 1208
77. D. Kromhout, E.J. Giltay, and J.M. Geleijnse n-3 Fatty acids and cardiovascular events after myocardial infarction N Engl J Med 363 2010 2015 2026
78. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 376 2010 1670 1681
79. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
80. K.K. Lee, L.E. Cipriano, D.K. Owens, A.S. Go, and M.A. Hlatky Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy Circulation 122 2010 1478 1487
81. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in PreventionAn Intervention Trial Evaluating Rosuvastatin) trial J Am Coll Cardiol 55 2010 1266 1273
82. C. Baigent, M.J. Landray, and C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
83. M. Jun, C. Foote, and J. Lv Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
84. S.A. Sorrentino, C. Besler, and L. Rohrer Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy Circulation 121 2010 110 122
85. R.S. Vasan, M.J. Pencina, and S.J. Robins Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community Circulation 120 2009 2414 2420
86. A. Ritsch, H. Scharnagl, and P. Eller Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study Circulation 121 2010 366 374
87. C.P. Cannon, S. Shah, and H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
88. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
89. S. Zoungas, A. Patel, and J. Chalmers Severe hypoglycemia and risks of vascular events and death N Engl J Med 363 2010 1410 1418
90. M.C. Riddle, W.T. Ambrosius, and D.J. Brillon Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial Diabetes Care 33 2010 983 990
91. H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
92. W.C. Cushman, G.W. Evans, and R.P. Byington Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
93. R.M. Cooper-DeHoff, Y. Gong, and E.M. Handberg Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 304 2010 61 68
94. G. Mancia Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Circulation 122 2010 847 849
95. M.A. Weber, G.L. Bakris, and K. Jamerson Cardiovascular events during differing hypertension therapies in patients with diabetes J Am Coll Cardiol 56 2010 77 85
96. J.J. McMurray, R.R. Holman, and S.M. Haffner Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
97. S. Kaul, A.F. Bolger, D. Herrington, R.P. Giugliano, and R.H. Eckel Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation J Am Coll Cardiol 55 2010 1885 1894
98. D.J. Graham, R. Ouellet-Hellstrom, and T.E. MaCurdy Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone JAMA 304 2010 411 418
99. R.R. Holman, S.M. Haffner, and J.J. McMurray Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1463 1476
100. W.P. James, I.D. Caterson, and W. Coutinho Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects N Engl J Med 363 2010 905 917
101. S.R. Smith, N.J. Weissman, and C.M. Anderson Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med 363 2010 245 256
102. M. Pignone, M.J. Alberts, and J.A. Colwell Aspirin for primary prevention of cardiovascular events in people with diabetes J Am Coll Cardiol 55 2010 2878 2886
103. F.G. Fowkes, J.F. Price, and M.C. Stewart Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848
104. M.J. Jardine, T. Ninomiya, and V. Perkovic Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial J Am Coll Cardiol 56 2010 956 965
105. D.L. Bhatt, B.L. Cryer, and C.F. Contant Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
106. E.M. Mahoney, K. Wang, and S.V. Arnold Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation 121 2010 71 79
107. C.P. Cannon, R.A. Harrington, and S. James Comparison of ticagrelor with clopidogrel in patients with a Planned Invasive Strategy for Acute Coronary Syndromes (PLATO): a randomised double-blind study Lancet 375 2010 283 293
108. R.F. Storey, D.J. Angiolillo, and S.B. Patil Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet Inhibition and Patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
109. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
110. W. Hueb, N. Lopes, and B.J. Gersh Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease Circulation 122 2010 949 957
111. B.R. Chaitman, R.M. Hardison, and D. Adler The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction Circulation 120 2009 2529 2540
112. M.A. Hlatky, D.B. Boothroyd, and K.A. Melsop Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial Circulation 120 2009 2550 2558
113. N.H. Pijls, W.F. Fearon, and P.A. Tonino Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study J Am Coll Cardiol 56 2010 177 184
114. T.G. Brott, R.W. Hobson Jr. , and G. Howard Stenting versus endarterectomy for treatment of carotid-artery stenosis N Engl J Med 363 2010 11 23
115. J. Ederle, J. Dobson, and R.L. Featherstone Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial Lancet 375 2010 985 997
116. L.H. Bonati, J. Dobson, and A. Algra Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data Lancet 376 2010 1062 1073
117. R.M. Greenhalgh, L.C. Brown, J.T. Powell, S.G. Thompson, D. Epstein, and M.J. Sculpher Endovascular versus open repair of abdominal aortic aneurysm N Engl J Med 362 2010 1863 1871
118. R.M. Greenhalgh, L.C. Brown, J.T. Powell, S.G. Thompson, and D. Epstein Endovascular repair of aortic aneurysm in patients physically ineligible for open repair N Engl J Med 362 2010 1872 1880